drugset / Trial / NCT00870870
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the number of participants whose cancer shrinks or disappears after treatment on the study.
Timeline
- Start
- 2009-03
- Primary completion
- 2012-04
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cixutumumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |